SMS Pharma.

{
  "main_header": {
    "sid": 517655,
    "name": "SMS Pharma.",
    "stock_name": "SMS Pharma.",
    "full_name": "SMS Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/sms-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "320.00",
    "chg": 4,
    "chgp": "1.27%",
    "dir": 1,
    "prev_price": "316.00",
    "mcapval": "2,979.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 532815,
    "symbol": "SMSPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE812G01025",
    "curr_date": "Feb 09",
    "curr_time": "",
    "bse_nse_vol": "5.97 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 09, 2026",
    "traded_date_str": "2026 02 09",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sms-pharma-517655-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are SMS Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-sms-pharmaceuticals-ltd-latest-results-good-or-bad-3827576",
        "imagepath": "",
        "date": "2026-02-08 19:13:11",
        "description": "SMS Pharmaceuticals Ltd's latest financial results for Q3 FY26 reveal a mixed operational performance. The company reported a consolidated net profit of ₹23.47 crore, reflecting a year-on-year growth of 28.67%. However, this figure represents a sequential decline of 7.27% compared to the previous quarter. Similarly, net sales for the quarter amounted to ₹210.45 crore, which is a notable year-on-year increase of 21.40%, but also shows a decline of 13.19% from the prior quarter.\n\nThe operating margin, excluding other income, improved to 20.74%, up from 19.16% in the same quarter last year, indicating effective cost management and operational efficiency. The profit after tax (PAT) margin also expanded to 11.02%, an increase from 9.85% year-on-year, suggesting that the company has been able to maintain profitability despite the fluctuations in sales.\n\nOn a nine-month basis, SMS Pharmaceuticals achieved consolid..."
      },
      {
        "title": "SMS Pharmaceuticals Q3 FY26: Strong YoY Growth Masks Sequential Dip Amid Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/sms-pharmaceuticals-q3-fy26-strong-yoy-growth-masks-sequential-dip-amid-valuation-concerns-3827012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SMSPharmaceutic_quaterlyResult_3827012.png",
        "date": "2026-02-07 20:46:54",
        "description": "SMS Pharmaceuticals Ltd., a Hyderabad-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹23.47 crores for Q3 FY26 (October-December 2025), marking a robust 28.67% year-on-year growth but a 7.27% sequential decline from the previous quarter. The company's stock, trading at ₹315.50 with a market capitalisation of ₹3,034 crores, has delivered impressive long-term returns of 139.65% over two years, yet faces valuation headwinds with a price-to-earnings ratio of 35x—significantly above the industry average of 32x."
      },
      {
        "title": "SMS Pharmaceuticals Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sms-pharmaceuticals-ltd-is-rated-hold-by-marketsmojo-3816297",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SMSPharmaceutic_mojoScore_3816297.png",
        "date": "2026-02-02 10:10:26",
        "description": "SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 02 February 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "SMS Pharmaceuticals Ltd Opens Strong with Significant Gap Up on 30 Jan 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-ltd-opens-strong-with-significant-gap-up-on-30-jan-2026-3811442",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SMSPharmaceutic_gapup_3811442.png",
        "date": "2026-01-30 11:35:15",
        "description": "SMS Pharmaceuticals Ltd commenced trading on 30 Jan 2026 with a notable gap up, opening 12.84% higher than its previous close, reflecting a robust start and positive market sentiment in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "SMS Pharmaceuticals Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sms-pharmaceuticals-ltd-is-rated-hold-by-marketsmojo-3799957",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SMSPharmaceutic_mojoScore_3799957.png",
        "date": "2026-01-22 10:10:23",
        "description": "SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "SMS Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-3797621",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SMSPharmaceutic_technicaldot_3797621.png",
        "date": "2026-01-21 08:01:57",
        "description": "SMS Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early 2026. Despite a recent day decline of 1.62% to ₹309.00, the stock’s technical indicators present a nuanced picture, reflecting both strength and caution within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "SMS Pharmaceuticals Ltd Technical Momentum Shifts to Bullish Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-ltd-technical-momentum-shifts-to-bullish-amid-mixed-market-signals-3795227",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SMSPharmaceutic_technicaldot_3795227.png",
        "date": "2026-01-20 08:02:41",
        "description": "SMS Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend across multiple timeframes. Despite a recent sharp intraday price decline, key technical indicators such as MACD and moving averages signal improving momentum, suggesting potential for further upside in the medium term."
      },
      {
        "title": "Why is SMS Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sms-pharmaceuticals-ltd-fallingrising-3794913",
        "imagepath": "",
        "date": "2026-01-20 00:42:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>The stock has underperformed significantly over the past week, registering a decline of 9.46%, compared to the Sensex’s modest fall of 0.75% during the same period. Today’s trading session opened with a gap down of 2.43%, signalling immediate bearish sentiment among investors. The share price touched an intraday low of ₹311.85, marking a 6.38% drop from the previous close. Notably, the weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting stronger selling interest at lower price levels.</p>\n<p>Despite this recent weakness, SMS Pharmaceuticals continues to maintain its position above its 50-day, 100-day, and 200-day moving averages, although it remains below the shorter-term 5-day..."
      },
      {
        "title": "SMS Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sms-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3791302",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/SMSPharmaceutic_technicaldot_3791302.png",
        "date": "2026-01-14 08:01:42",
        "description": "SMS Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from bullish to mildly bullish territory. Despite a recent day decline of 2.37%, the stock’s longer-term technicals and price action suggest a complex interplay of bullish and bearish forces that investors should carefully analyse."
      }
    ],
    "total": 714,
    "sid": "517655",
    "stock_news_url": "https://www.marketsmojo.com/news/sms-pharmaceuticals-517655"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting And Financial Results",
      "datetime": "07-Feb-2026",
      "details": "Financial results for the quarter ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Statement Of Deviation Or Variation For The Quarter Ended December 31 2025",
      "datetime": "07-Feb-2026",
      "details": "Statement of Deviation or variation for the quarter ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter Ended 31St December 2025",
      "datetime": "07-Feb-2026",
      "details": "Financial Results for the quarter ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "SMS Pharmaceuticals Ltd has declared <strong>40%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "SMS Pharmaceuticals Ltd has announced <strong>1:10</strong> stock split, ex-date: 17 Dec 15",
          "dt": "2015-12-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are SMS Pharmaceuticals Ltd latest results good or bad?

2026-02-08 19:13:11

SMS Pharmaceuticals Ltd's latest financial results for Q3 FY26 reveal a mixed operational performance. The company reported a consolidated net profit of ₹23.47 crore, reflecting a year-on-year growth of 28.67%. However, this figure represents a sequential decline of 7.27% compared to the previous quarter. Similarly, net sales for the quarter amounted to ₹210.45 crore, which is a notable year-on-year increase of 21.40%, but also shows a decline of 13.19% from the prior quarter. The operating margin, excluding other income, improved to 20.74%, up from 19.16% in the same quarter last year, indicating effective cost management and operational efficiency. The profit after tax (PAT) margin also expanded to 11.02%, an increase from 9.85% year-on-year, suggesting that the company has been able to maintain profitability despite the fluctuations in sales. On a nine-month basis, SMS Pharmaceuticals achieved consolid...

Read full news article

SMS Pharmaceuticals Q3 FY26: Strong YoY Growth Masks Sequential Dip Amid Valuation Concerns

2026-02-07 20:46:54

SMS Pharmaceuticals Ltd., a Hyderabad-based active pharmaceutical ingredient (API) manufacturer, reported a consolidated net profit of ₹23.47 crores for Q3 FY26 (October-December 2025), marking a robust 28.67% year-on-year growth but a 7.27% sequential decline from the previous quarter. The company's stock, trading at ₹315.50 with a market capitalisation of ₹3,034 crores, has delivered impressive long-term returns of 139.65% over two years, yet faces valuation headwinds with a price-to-earnings ratio of 35x—significantly above the industry average of 32x.

Read full news article

SMS Pharmaceuticals Ltd is Rated Hold by MarketsMOJO

2026-02-02 10:10:26

SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 02 February 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

SMS Pharmaceuticals Ltd Opens Strong with Significant Gap Up on 30 Jan 2026

2026-01-30 11:35:15

SMS Pharmaceuticals Ltd commenced trading on 30 Jan 2026 with a notable gap up, opening 12.84% higher than its previous close, reflecting a robust start and positive market sentiment in the Pharmaceuticals & Biotechnology sector.

Read full news article

SMS Pharmaceuticals Ltd is Rated Hold by MarketsMOJO

2026-01-22 10:10:23

SMS Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

SMS Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals

2026-01-21 08:01:57

SMS Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early 2026. Despite a recent day decline of 1.62% to ₹309.00, the stock’s technical indicators present a nuanced picture, reflecting both strength and caution within the Pharmaceuticals & Biotechnology sector.

Read full news article

SMS Pharmaceuticals Ltd Technical Momentum Shifts to Bullish Amid Mixed Market Signals

2026-01-20 08:02:41

SMS Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend across multiple timeframes. Despite a recent sharp intraday price decline, key technical indicators such as MACD and moving averages signal improving momentum, suggesting potential for further upside in the medium term.

Read full news article

Why is SMS Pharmaceuticals Ltd falling/rising?

2026-01-20 00:42:29

Recent Price Movement and Market Performance

The stock has underperformed significantly over the past week, registering a decline of 9.46%, compared to the Sensex’s modest fall of 0.75% during the same period. Today’s trading session opened with a gap down of 2.43%, signalling immediate bearish sentiment among investors. The share price touched an intraday low of ₹311.85, marking a 6.38% drop from the previous close. Notably, the weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting stronger selling interest at lower price levels.

Despite this recent weakness, SMS Pharmaceuticals continues to maintain its position above its 50-day, 100-day, and 200-day moving averages, although it remains below the shorter-term 5-day...

Read full news article

SMS Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-01-14 08:01:42

SMS Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from bullish to mildly bullish territory. Despite a recent day decline of 2.37%, the stock’s longer-term technicals and price action suggest a complex interplay of bullish and bearish forces that investors should carefully analyse.

Read full news article

View All News